Bingham Kate 的 Form 4/A 修正申報
修正Bicycle Therapeutics PLC（BCYC），2021/7/20 申報
- 申報編號
- 0000899243-21-028984
- 申報時間
- 2021/7/20
- 交易日
- 2021/7/13-7/14
- 申報延遲
- 7 天
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
- 原始申報日
- 2021/7/15
這份申報列了 4 筆非衍生性交易。公開市場賣出合計 $152.7 萬。交易後 7 天申報。
這份修正申報取代了 0000899243-21-028546（2021/7/15 申報）。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Bingham KateCIK 0001185040 | 董事 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2021/7/13 | Ordinary Shares | S賣出處分 | −588 | $33.50 | −$19,698 | 1,875,049 | 間接 | |
| 2021/7/14 | Ordinary Shares | S賣出處分 | −43,378 | $34.01 | −$1,475,285.78 | 1,831,671 | 間接 | |
| 2021/7/13 | Ordinary Shares | S賣出處分 | −12 | $33.50 | −$402 | 39,625 | 間接 | |
| 2021/7/14 | Ordinary Shares | S賣出處分 | −917 | $34.01 | −$31,187.17 | 38,708 | 間接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.
- F2
These shares were sold by SVLS V LP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein.
- F3
These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.
- F4
These shares were sold by SVLS V SPP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein.
備註
The original Form 4 filed on July 15, 2021 is amended by this Form 4 amendment to reflect Ms. Bingham's resignation from the Board of Directors effective as of the Annual Meeting held on June 28, 2021. As a result of her resignation, Ms. Bingham is no longer subject to Section 16 reporting requirements.